GlassScriptPhysician profile
Christa Clay
NPI 1982472106
$2,641.16
in general payments reported to CMS, 2019-2025
26 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $762 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,372 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,371.84 |
| Education | $269.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $573.49 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $258.90 | 2025 | |
| Abbvie INC. | $226.95 | 2025 | |
| Emd Serono, INC. | $215.34 | 2025 | |
| Pfizer INC. | $194.23 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.43 | 2025 | |
| Eisai INC. | $139.10 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $121.35 | 2024 | Lumryz |
| Argenx US, INC. | $112.52 | 2025 | Vyvgart Hytrulo |
| Sk Life Science, INC. | $74.74 | 2024-2025 | Xcopri |
| Novartis Pharmaceuticals Corporation | $60.51 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $55.12 | 2024-2025 | Ingrezza |
| Ucb, INC. | $54.76 | 2025 | Rystiggo |
| Medtronic, INC. | $54.00 | 2025 | Percept PC Brainsense |
| Otsuka America Pharmaceutical, INC. | $43.76 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.42 | 2024 | Hyqvia |
| Vanda Pharmaceuticals INC. | $34.03 | 2025 | Ponvory |
| Lundbeck LLC | $33.80 | 2024-2025 | Rexulti, Vyepti |
| Genentech USA, INC. | $33.77 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Activase |
| Lilly USA, LLC | $32.13 | 2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $30.76 | 2024-2025 | Rytary, Crexont |
| Neurelis, INC. | $29.28 | 2024 | Valtoco |
| Mdd US Operations, LLC | $24.79 | 2025 | Gocovri |
| Genentech, INC. | $22.73 | 2024 | Ocrevus |
| Acadia Pharmaceuticals INC | $21.96 | 2024 | Nuplazid |
| Axsome Therapeutics, INC. | $17.29 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christa Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.